Close Menu Congressman Kurt Schrader

Legislation

Lower Drug Costs through Competition Act

H.R.749

The Lower Drug Costs Through Competition Act will incentivize drug makers to develop generic drugs when competition currently does not exist, or when there is a drug shortage. The bill will bring new generic drugs to the market where there might otherwise be little incentive to compete because there is a small patient population for the drug, or the costs of development might be too high. One of the most well-known examples of this happened in 2015 when Turing Pharmaceuticals, led by hedge fund manager Martin Shkreli, jacked the price of Daraprim – an anti-parasitic drug that’s most commonly used to treat and prevent certain infections in HIV positive patients –from $13.50 to $750 overnight. One lesser known example occurred as communities across the country, including in Oregon and Florida, have faced lead-tainted water crises, Valeant Pharmaceuticals raised the price on a lead poisoning treatment by 2,700%. And in the fall of 2016, Mylan notoriously came under fire when the company raised the cost of the EpiPen – the well-known epinephrine injection device – by more than 400%. According to the CDC, there are more than 300,000 food-allergy related ambulatory-care visits each year among children, and more than 15 million people in the US have been diagnosed with some type of food allergy. The first and often only lifesaving line of defense when anaphylaxis strikes is the EpiPen.
 
In each of these instances, there was no generic on the market at the time of the disproportionate price hikes. This bill incentivizes companies to develop these generic drugs by creating a new Priority Review Voucher for generic drugs. The voucher would be awarded to manufacturers that bring a drug to market where there is no current competition.